Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase

Objectives The ubiquitously expressed non-receptor protein tyrosine phosphatase SHP2, encoded by PTPN11, is involved in signal transduction downstream of multiple growth factor, cytokine and integrin receptors. Its requirement for complete RAS-MAPK activation and its role as a negative regulator of JAK-STAT signaling have established SHP2 as an essential player in oncogenic signaling pathways. Recently, novel potent allosteric SHP2-inhibitors have been presented as a viable therapeutic option for RTK-driven cancers, but were shown to be ineffective in KRAS mutant tumor cell lines in vitro.

Source: Pancreatology - June 1, 2018 Category: Gastroenterology Authors: Dietrich Ruess, Guus Heynen, Katrin Ciecielski, Walter Birchmeier, Roland Schmid, Hana Alg ül Tags: Session 11. Molecular mechanisms of pancreatic cancer - free papers Source Type: research